Surgery Partners (NASDAQ:SGRY) Posts Earnings Results, Beats Expectations By $0.05 EPS

Surgery Partners (NASDAQ:SGRY) posted its quarterly earnings data on Monday. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05, FiscalAI reports. The company had revenue of $815.30 million for the quarter, compared to the consensus estimate of $820.96 million. Surgery Partners had a negative net margin of 2.63% and a positive return on equity of 0.88%. The firm’s revenue was down .8% compared to the same quarter last year. During the same period last year, the company earned $0.13 earnings per share.

Surgery Partners Trading Up 14.0%

NASDAQ SGRY opened at $26.45 on Tuesday. Surgery Partners has a 12 month low of $11.41 and a 12 month high of $27.23. The company has a current ratio of 1.95, a quick ratio of 1.78 and a debt-to-equity ratio of 1.18. The stock has a 50 day moving average of $16.29 and a 200-day moving average of $14.88. The company has a market cap of $3.46 billion, a PE ratio of 115.80 and a beta of 1.85.

Key Stories Impacting Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Higher merger price is the main catalyst. The amended agreement reportedly increases the per-share consideration to $25 from $23.50 after a competing bid, with the Bon Secours affiliate’s transaction valued at up to $6 billion. A higher offer supports the deal’s value for shareholders, though completion remains a risk. Article: Surgery Partners Secures Improved Merger Terms
• Positive Sentiment: Adjusted Q3 earnings topped estimates. Surgery Partners reported adjusted EPS of $0.16, above the cited FactSet estimate of $0.11, providing some earnings support. Article: Q3 Adjusted EPS Earnings Flash
• Neutral Sentiment: Cash generation improved, despite weaker operating results. Operating cash flow was reported at $103.5 million and cash balances rose to $354.5 million, while revenue was $815.3 million—below estimates and slightly down year over year. Article: Q3 2026 Earnings Results
• Negative Sentiment: Profitability remains a concern, and a cash-flow valuation flags downside. The company reported a $21.1 million net loss attributable to common shareholders, with higher costs and lower operating profit. A separate analysis estimates SGRY may be 13% overvalued based on cash flow, which could limit further gains. Article: Surgery Partners Stock Could Be 13% Overvalued on Cash Flow

Insider Transactions at Surgery Partners

In other news, Director Teresa DeLuca purchased 10,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were purchased at an average cost of $14.35 per share, with a total value of $143,500.00. Following the completion of the transaction, the director owned 66,843 shares of the company’s stock, valued at $959,197.05. The trade was a 17.59% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on SGRY. Cantor Fitzgerald downgraded shares of Surgery Partners from an “overweight” rating to a “hold” rating in a research report on Monday, October 26th. Zacks Research cut shares of Surgery Partners from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 10th. Weiss Ratings upgraded shares of Surgery Partners from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. Stonex Financial cut Surgery Partners from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 27th. Finally, TD Cowen cut Surgery Partners from a “strong-buy” rating to a “hold” rating in a report on Saturday, October 31st. Three research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $20.14.

About Surgery Partners

Surgery Partners, Inc is a U.S. healthcare services company that owns and operates ambulatory surgery centers and surgical hospitals. Its facilities provide outpatient and inpatient surgical care across a range of specialties.

The company’s services include surgical procedures and related care delivered in partnership with physicians and healthcare professionals. Its network serves patients in multiple states across the United States.

Founded in 2004, Surgery Partners has expanded its network through acquisitions and partnerships with physicians and health systems.